AFT broadens R&D pipeline with new product candidate

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com





22 December 2023


AFT broadens R&D pipeline with new product candidate in
Burning Mouth Syndrome

AFT Pharmaceuticals (ASX: AFP, NZX: AFT) today announces that it has entered into a
partnership with one of its research and development partners, Belgium’s Hyloris
Pharmaceuticals. to develop a novel locally acting product for the treatment of
Burning Mouth Syndrome (BMS).
Under the terms of the agreement, AFT and Hyloris will co-invest for the development
of HY-090 for the purpose of registration, approval and commercialisation. Under the
terms of the agreement, Hyloris shall be accountable for the execution and
coordination of formulation and related activities and AFT shall assume the
responsibility for the management of clinical trials, overseeing all aspects to ensure
effective planning, execution, and monitoring throughout the trial lifecycle.
For product commercialisation strategies, Hyloris shall be responsible for Europe, jointly
responsible with AFT for the United States and AFT responsible for all other global
territories.
AFT Managing Director Dr Hartley Atkinson says: “This collaboration brings together the
strengths of AFT and Hyloris, combining strong internal R&D capabilities and solid
expertise in clinical trial management building on our current Maxigesic IV partnership.
I look forward to the success and growth it will bring to our companies and importantly
assists our international expansion goals."
“We had previously flagged to the market at our half year reporting that we were
targeting increasing our R&D pipeline with two projects under diligence. This was one
of those projects but we confirm that we are still working to complete diligence on a
further three projects. We see that further R&D projects are important to drive our long-
term global expansion”, said Dr Atkinson.
Burning mouth syndrome (BMS) is characterized by burning pain in a normal-
appearing oral mucosa lasting at least four to six months. The condition is idiopathic,
and the underlying pathophysiology is not well understood. Patients with burning
mouth syndrome commonly experience changes in taste. The reported prevalence
ranges from 0.7 to 5% or approximately 2,800,000 individuals in the US and occurs more
frequently in women than men, with a female to male ratio of 7:1. Prevalence

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com

increases with age in both men and women, with the highest prevalence reported in
postmenopausal women aged 60–69 years.

Released for and on behalf of AFT Pharmaceuticals limited by Malcolm Tubby, Chief
Financial Officer.
For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

About AFT Pharmaceuticals www.aftpharm.com
AFT Pharmaceuticals are a growing multinational pharmaceutical company that
develops, markets, and distributes a broad portfolio of pharmaceutical products
across a wide range of therapeutic categories which are distributed across all major
pharmaceutical distribution channels: over the counter, prescription, and hospital.
AFT Pharmaceutical's product portfolio comprises both proprietary and in -licensed
products, and includes patented, branded, and generic drugs.